OSAGRAND 3mg / 3ml injectible solution medication leaflet

M05BA06 ibandronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates

Ibandronic acid is a medication from the bisphosphonate class used for the prevention and treatment of osteoporosis, particularly in postmenopausal women, to reduce the risk of bone fractures, especially in the spine. It is also used to treat hypercalcemia associated with bone metastases in certain types of cancer.

Ibandronic acid works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption, helping to maintain bone density and prevent bone loss. It is available in tablet or injection form, with administration being periodic (monthly or quarterly, depending on the indication).

Side effects may include muscle or joint pain, gastrointestinal irritation (such as heartburn or nausea), and, in rare cases, osteonecrosis of the jaw. It is important to take the medication as directed by a doctor, and patients should remain upright for at least 30-60 minutes after oral administration to reduce the risk of esophageal irritation.

General data about OSAGRAND 3mg / 3ml

Substance: ibandronic acid

Date of last drug list: 01-06-2025

Commercial code: W57484001

Concentration: 3mg / 3ml

Pharmaceutical form: injectible solution

Quantity: 1

Product type: generic

Price: 123.60 RON

Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

Manufacturer: ZENTIVA K.S. - REPUBLICA CEHA

Holder: ZENTIVA K.S. - REPUBLICA CEHA

Number: 9963/2017/01

Shelf life: 2 years

Concentrations available for ibandronic acid

150mg, 1mg/1ml, 2.5mg, 2mg, 2mg/2ml, 3mg, 3mg/3ml, 50mg, 6mg, 6mg/6ml

Compensation lists for OSAGRAND 3mg / 3ml ZENTIVA

D - Sublist D with 20% discount from the reference price

Price

Copayment

Patient

123.60 RON

14.00 RON

109.60 RON